1. Labcorp will release Q2 2025 results on July 24, 2025. 2. A live conference call will occur to discuss financial results. 3. Labcorp supports over 75% of new FDA drug approvals in 2024. 4. The company performs over 700 million tests annually globally. 5. Labcorp aims to improve health through diagnostics and drug development.
The upcoming earnings release typically raises investor expectations. Positive earnings results could lead to a price increase as seen historically with Labcorp.
Anticipation of earnings can drive trading behavior. The context of significant drug approvals adds to positive sentiment around Labcorp.
Earnings reports typically affect stock price in the immediate aftermath. Historical examples show traders react quickly to new information within days.
BURLINGTON, N.C., June 26, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
The call will be webcast live on the Labcorp Investor Relations website. Participants may also register for the call by clicking on this link, to receive the dial-in numbers and unique PIN to access the call. The webcast and dial-in are listen-only. It is recommended that participants join 10 minutes prior to the start, although participants may register and join at any time during the call.
A replay of the webcast will be available approximately two hours after the conclusion of the live event and will be available until July 11, 2026. To access the webcast recording, visit the Labcorp Investor Relations website.
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.